Kairos Pharma’s (KAPA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Kairos Pharma (NYSEAMERICAN:KAPA) in a research note released on Thursday,Benzinga reports. D. Boral Capital currently has a $9.00 price target on the stock.

Kairos Pharma Stock Up 3.1 %

Kairos Pharma stock opened at $1.01 on Thursday. The firm has a 50 day moving average of $1.34. Kairos Pharma has a twelve month low of $0.85 and a twelve month high of $4.00.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.